Literature DB >> 19180635

Primary tumor thickness as a risk factor for contralateral cervical metastases in T1/T2 oral tongue squamous cell carcinoma.

Carol M Bier-Laning1, Ramon Durazo-Arvizu, Kamil Muzaffar, Guy J Petruzzelli.   

Abstract

OBJECTIVES/HYPOTHESIS: Contralateral cervical metastases represent an avoidable source of failure in squamous cell carcinoma (SCCa) of the oral tongue. We sought to identify risk factors for the development of contralateral cervical metastases in T1/T2 oral tongue SCCa. STUDY
DESIGN: Retrospective review.
METHODS: We reviewed the medical records of 50 sequential cases of Stage I/II SCCa of the oral tongue treated with surgery between 1983 and 2003 at Loyola University Medical Center and Hines VA Hospital. Clinical staging, primary tumor thickness, results of neck dissection, adjuvant treatment, site and date of recurrence, and final outcome were recorded. Follow-up ranged from 0.2 to 17 years, with a mean of 5 years. Data were analyzed using multivariate logistic, Cox regression analysis, and a classification and logistic regression tree analysis.
RESULTS: The odds ratio for risk of developing contralateral neck metastasis was 5% for each 1 mm increase in tumor thickness (P = .68). The risk did not change when controlling for the presence of ipsilateral metastasis. There was a significant relationship between contralateral cervical metastases and the development of recurrent disease at any site (P = .005). Classification tree analysis determined the risk for contralateral metastases and was greatest for patients with tumors > 3.75 mm thick and < or = 9.5 mm thick.
CONCLUSIONS: This report is the first to our knowledge that evaluates thickness as a risk factor for contralateral cervical metastasis in oral tongue SCCa. We recommend consideration be given to treating the contralateral neck in cases where the primary tumor is > 3.75 mm thick.

Entities:  

Mesh:

Year:  2009        PMID: 19180635     DOI: 10.1002/lary.20141

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients.

Authors:  Waseem Jerjes; Tahwinder Upile; Aviva Petrie; Andrew Riskalla; Zaid Hamdoon; Michael Vourvachis; Kostas Karavidas; Amrita Jay; Ann Sandison; Gareth J Thomas; Nicholas Kalavrezos; Colin Hopper
Journal:  Head Neck Oncol       Date:  2010-04-20

2.  Predicting the Prognosis of Oral Tongue Carcinoma Using a Simple Quantitative Measurement Based on Preoperative MR Imaging: Tumor Thickness versus Tumor Volume.

Authors:  H Hu; K-L Cheng; X-Q Xu; F-Y Wu; Y-S Tyan; C-H Tsai; C-Y Shen
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-02       Impact factor: 3.825

3.  Neurovascular Invasion and Histological Grade Serve as the Risk Factors of Cervical Lymph Node Metastases in Early Tongue Squamous Cell Carcinoma.

Authors:  Kailiu Wu; Xi Yang; Liwen Li; Min Ruan; Wei Liu; Wei Lu; Chenping Zhang; Siyi Li
Journal:  Mol Neurobiol       Date:  2015-04-25       Impact factor: 5.590

4.  Tumour thickness in oral cancer using an intra-oral ultrasound probe.

Authors:  Wouter L Lodder; Hendrik J Teertstra; Ing B Tan; Frank A Pameijer; Ludi E Smeele; Marie-Louise F van Velthuysen; Michiel W M van den Brekel
Journal:  Eur Radiol       Date:  2010-08-03       Impact factor: 5.315

5.  PARVB overexpression increases cell migration capability and defines high risk for endophytic growth and metastasis in tongue squamous cell carcinoma.

Authors:  A Eslami; K Miyaguchi; K Mogushi; H Watanabe; N Okada; H Shibuya; H Mizushima; M Miura; H Tanaka
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640

6.  Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases.

Authors:  Christian Flörke; Aydin Gülses; Christina-Randi Altmann; Jörg Wiltfang; Henning Wieker; Hendrik Naujokat
Journal:  Curr Oncol       Date:  2021-05-14       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.